During a widely anticipated U.K. Parliamentary hearing, Vertex Pharmaceuticals (VRTX) chief executive Jeff Leiden promised to offer “new ideas” for breaking a long-running stalemate over access to a cystic fibrosis medicine when he meets with a government official next week.

“I’m going to come to the meeting with new ideas,” Leiden said about his planned meeting on Monday with Secretary of State Matt Hancock. “And meantime, we would guarantee access to patients at a discount to our list price. I want to get (a pair of government health agencies) back to the table. There’s no reason we can’t find a solution here in England.”

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy